MedTrace Logo

Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject

NCT02303509 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2014-12-01

No results posted yet for this study

Summary

To evaluate the safety and tolerability of UCB5857. Part 1 of the study explores single doses of the drug. Part 2 of the study explores giving the drug every day for 14 days. The study uses healthy and psoriasis subjects.

Conditions

Interventions

DRUG

UCB5857 Part 1

Active substance: UCB5857 Pharmaceutical form: Capsule Concentration: 1 mg, 5 mg, 10 mg or 15 mg Route of administration: Oral

DRUG

UCB5857 Part 2

Active substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 8 mg, 15 mg Route of administration: Oral

OTHER

Placebo

Active substance: Placebo Pharmaceutical form: Capsule Concentration: Avicel PH 102, 50 mg Route of administration: Oral

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB, Cares · 1-877-822-9493

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02303509 on ClinicalTrials.gov